Kato (Hong Kong) Holdings Ltd. 2189

BOSTON, October 02, 2026--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC

CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On September 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to,

Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25. Kidney Week 2026 Late-Breaking Poster Details Title: Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antag

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option P

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026. Late-Breaking Clinical Trial Presentations Title: Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Res

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Veracyte, Inc. recently presented retrospective ancillary Phase III NRG/RTOG 0815 trial data at the 2026 ASTRO meeting, showing that its Decipher Prostate Genomic Classifier can stratify which intermediate-risk prostate cancer patients benefit from adding short-term androgen deprivation therapy to dose-escalated radiation, with Level 1B1 prognostic and predictive evidence. The findings suggest Decipher could help physicians better balance treatment benefit against the metabolic and...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 37% over the past six months, topping the S&P 500 by 20.7 percentage points.

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the Company’s common stock

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted

FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company’s common stock with an exercise price of $7.22, the closing trading price of the Company’s common s

The changes reflect new views on restaurant demand, retail traffic, travel growth, drug risks and competition in financial data.

The obesity drug market is so large that only a small market share could lead to substantive price appreciation for the stock.

LONDON & NEW YORK, October 02, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and re

Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.

Novartis (NYSE:NVS) has entered into a licensing agreement with Chinese biotechnology company Abogen covering an experimental RNA-based therapy and other potential treatments developed using Abogen’s technology platform. Under the agreement, Abogen will receive an upfront payment of $575 million and could receive an additional $7.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Summit Therapeutics (SMMT) is back in focus after AstraZeneca agreed to invest about US$2 billion through convertible preferred stock and entered a non exclusive clinical collaboration built around ivonescimab combinations. Summit Therapeutics’ share price has been volatile, with a 6.9% 7 day share price return and a 14.3% 30 day share price return. However, the year to date share price return is down 4.7%, while the 1 year total shareholder return has declined 22.1%. This follows very large...

WELL Presentation Time: 9:00 AM ET in Track 1.Vancouver, British Columbia--(Newsfile Corp. - October 2, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce its participation at the upcoming Cantech Investment Conference on Thursday, October 8, 2026, at the Arcadian...

SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it expanded into Florida with the acquisition of the following operations: Bay Park Post-Acute and Rehabilitation, a 101-bed skilled nursing fa